361 Capital’s Sarepta Therapeutics SRPT Stock Holding History

361 Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-42,200	Closed	-$1.91M	–	298
2017 Q3	$1.91M	Buy	+42,200	New	+$1.69M	0.37%	152

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

361 Capital's SRPT Position: Q4 2017 in Review

361 Capital sold out of Sarepta Therapeutics (SRPT) in Q4 2017, closing a stake of 42,200 shares — an estimated $1.91M sold.

361 Capital first reported a position in SRPT in Q3 2017 and held it in 1 quarter. The position peaked at $1.91M in Q3 2017. 254 funds tracked by Wall St. Rank hold SRPT as of Q4 2017.

361 Capital reported no remaining Sarepta Therapeutics position as of Q4 2017 after selling out during the quarter.
361 Capital sold 42,200 Sarepta Therapeutics shares in Q4 2017, an estimated $1.91M.
361 Capital first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 1 quarter.
361 Capital's Sarepta Therapeutics position peaked at $1.91M in Q3 2017.
254 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2017.

Based on 361 Capital's 13F filing for Q4 2017, filed 14 Feb 2018.